References
- Chi P , AllisCD , WangGG . Covalent histone modifications – miswritten, misinterpreted and mis-erased in human cancers . Nat. Rev. Cancer10 ( 7 ), 457 – 469 ( 2010 ).
- Arrowsmith CH , BountraC , FishPV , LeeK , SchapiraM . Epigenetic protein families: a new frontier for drug discovery . Nat. Rev. Drug Discov.11 ( 5 ), 384 – 400 ( 2012 ).
- Prinjha RK , WitheringtonJ , LeeK . Place your BETs: the therapeutic potential of bromodomains . Trends Pharmacol. Sci.33 ( 3 ), 146 – 153 ( 2012 ).
- Belkina AC , DenisGV . BET domain co-regulators in obesity, inflammation and cancer . Nat. Rev. Cancer12 ( 7 ), 465 – 477 ( 2012 ).
- Zhu J , GaihaGD , JohnSPet al. Reactivation of latent HIV-1 by inhibition of BRD4 . Cell Rep.2 ( 4 ), 807 – 816 ( 2012 ).
- Matzuk MM , MckeownMR , FilippakopoulosPet al. Small-molecule inhibition of BRDT for male contraception . Cell150 ( 4 ), 673 – 684 ( 2012 ).
- Delmore JE , IssaGC , LemieuxMEet al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc . Cell146 ( 6 ), 904 – 917 ( 2011 ).
- Lockwood WW , ZejnullahuK , BradnerJE , VarmusH . Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins . Proc. Natl Acad. Sci. USA109 ( 47 ), 19408 – 19413 ( 2012 ).
- Filippakopoulos P , QiJ , PicaudSet al. Selective inhibition of BET bromodomains . Nature468 ( 7327 ), 1067 – 1073 ( 2010 ).
- Nicodeme E , JeffreyKL , SchaeferUet al. Suppression of inflammation by a synthetic histone mimic . Nature468 ( 7327 ), 1119 – 1123 ( 2010 ).
- Dewoskin VA , MillionRP . The epigenetics pipeline . Nat. Rev. Drug Discov.12 ( 9 ), 661 – 662 ( 2013 ).
- Picaud S , DaCosta D , ThanasopoulouAet al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains . Cancer Res.73 ( 11 ), 3336 – 3346 ( 2013 ).
- Bamborough P , DialloH , GoodacreJDet al. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides . J. Med. Chem.55 ( 2 ), 587 – 596 ( 2012 ).
- Lucas X , WohlwendD , HugleMet al. 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading . Angew Chem. Int. Ed. Engl.52 ( 52 ), 14055 – 14059 ( 2013 ).
- Ott CJ , KoppN , BirdLet al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia . Blood120 ( 14 ), 2843 – 2852 ( 2012 ).
- Dawson MA , PrinjhaRK , DittmannAet al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia . Nature478 ( 7370 ), 529 – 533 ( 2011 ).
- Zuber J , ShiJ , WangEet al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia . Nature478 ( 7370 ), 524 – 528 ( 2011 ).
- Goupille O , PenglongT , LefevreCet al. BET bromodomain inhibition rescues erythropoietin differentiation of human erythroleukemia cell line UT7 . Biochem. Biophys. Res. Commun.429 ( 1–2 ), 1 – 5 ( 2012 ).
- Martin MP , OlesenSH , GeorgGI , SchonbrunnE . Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains . ACS Chem. Biol.8 ( 11 ), 2360 – 2365 ( 2013 ).
- Wyspianska BS , BannisterAJ , BarbieriIet al. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms . Leukemia28 ( 1 ), 88 – 97 ( 2014 ).
- Ververis K , HiongA , KaragiannisTC , LicciardiPV . Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents . Biologics7 , 47 – 60 ( 2013 ).